Buy Natdac 30 mg (Daclatasvir) Online, Daclatasvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle.Daclahep is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis.Daclahep is given together with another drug called Sovaldi (sofosbuvir).
$135.00 – $380.00
What is Natdac?
Natdac (Daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Natdac is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis. It is given together with another drug called Sovaldi (sofosbuvir).
How does Natdac work?
Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Daclatasvir must be used in combination with other medicines that attack the hepatitis C virus in different ways. If daclatasvir is used on its own there is a high chance that the hepatitis C virus will become resistant to it.
What is Natdac used for?
Natdac (Daclatasvir) is used to treat chronic hepatitis C infections (genotype 1, 3 and 4) in adults with uncomplicated liver disease whose liver is still functioning correctly (compensated liver disease). It may be used in people who have not yet received treatment for their hepatitis C, or for people whose disease has not improved with previous treatment. It may be used in combination with sofosbuvir (Sovaldi), either with or without ribavirin (Rebetol), or with ribavirin plus peginterferon alfa (ViraferonPeg or Pegasys).
Serious drug interactions can occur when certain medicines are used together with daclatasvir. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.
Before taking this medicine
You should not use Natdac if you are allergic to daclatasvir. If you take daclatasvir with sofosbuvir, there may be other reasons you should not take this combination treatment. Tell your doctor about all your medical conditions.
Some medicines can interact with Natdac and should not be used at the same time. Your doctor may need to change your treatment plan if you use any of the following drugs: rifampin, carbamazepine, phenytoin.
To make sure Natdac is safe for you, tell your doctor if you have:
It is not known whether Natdac will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether daclatasvir passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
Natdac is not approved for use by anyone younger than 18 years old
How is Natdac taken?
Daclatasvir is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a doctor who has experience treating hepatitis C. People with HCV genotypes 1 or 4 who are being treated for the first time and do not have liver cirrhosis should take daclatasvir plus sofosbuvir for 12 weeks. Due to limited clinical trial data, there is still uncertainty about the best way to treat people with genotypes 2, 3 or 4.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call to your doctor.
What should I avoid while taking Natdac?
Taking It will not prevent you from passing hepatitis C to other people. Do not have unprotected s** or share razors or toothbrushes. Talk with your doctor about safe ways to prevent HCV transmission during s**. Sharing drug or medicine needles is never safe, even for a healthy person.
Natdac side effects
Get emergency medical help if you have signs of an allergic reaction to Natdac: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Q. What is the Generic Name for the trade name drug “Daklinza” ?
A. Daclatasvir mepesuccinate is Generic Name for the trade name drug Natdac.
Q. What is the Manufacturer Name of Natdac ?
A. Natdac is manufactured by Natco Pharma, India
Q. Is Natdac approved by FDA?
A. Yes, It is approved by FDA.
Q. What is the dosage and form of Natdac is available?
A. It is available 30 mg & 60 mg film-coated tablets
GenMedicare is able to source Natdac Brentuximab Vedotin (Cancer Treatment Medicines) from across the globe, and has ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
GenMedicare is able to dispense any valid prescription in shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to Patients address only from India.
Is Natdac available in India?
It is a pharmaceutical drug that legally requires a medical prescription to be dispensed.
GenMedicare facilitates Export of cancer medicines on the named patient supply. GenMedicare is facilitator providing input
Natdac can be made available Europe, USA and Australia, GenMedicare can facilitate the supply of Natdac(prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please email us for bulk discount, We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
How order will be confirmed ?
The order will be confirmed only after the receipt of
Natdac From us.
Before contacting us please take into account that the medicine has to be prescribed by a doctor, and you must provide the prescription to us and we will verify it with your doctor.
On 17th December 2105 Natco Pharma got approval for generic Daclatasvir Dihydrochloride (“Daclatasvir”) tablets, Natdac 30mg & Natdac 60mg, from Drugs Controller General (India). Daclatasvir (Natdac) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.
U.S. Food and Drug Administration approved Natdac (Daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015 . Natdac (Daclatasvir) is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
Natco Pharma, India